- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06545955
En åpen fase 2-forsøk for å evaluere intravesikal Nadofaragene Firadenovec alene eller i kombinasjon med kjemoterapi eller immunterapi hos deltakere med høygradig BCG som ikke reagerer, ikke-muskelinvasiv blærekreft (ABLE-22)
En fase 2, randomisert, multisenter, åpen etikettforsøk for å evaluere sikkerheten og effekten av intravesikal Nadofaragene Firadenovec alene eller i kombinasjon med kjemoterapi eller immunterapi hos deltakere med høygradig Bacillus Calmette-Guerin-terapi (BCG) som ikke reagerer ikke-muskelinvasiv Blærekreft (NMIBC)
The pivotal phase 3 trial (rAd-IFN-CS 003) evaluating the efficacy of nadofaragene firadenovec showed that 55 (53.4%) of 103 subjects with CIS ± high-grade Ta/T1 achieved a complete response (CR) at 3 months. In this trial, the safety and efficacy of intravesical instillation of nadofaragene firadenovec alone or in combination with chemotherapy or immunotherapy will be evaluated in participants with NMIBC CIS (± high-grade Ta/T1).
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
- Navn: Ferring Pharmaceuticals
- Telefonnummer: 833-548-1402 (US/Canada)
- E-post: disclosure@ferring.com
Studer Kontakt Backup
- Navn: Ferring Pharmaceuticals
- Telefonnummer: +1862-286-5200 (not US/Canada)
- E-post: disclosure@ferring.com
Studiesteder
-
-
Alberta
-
Calgary, Alberta, Canada, T2V 1P9
- Rekruttering
- Prostate Cancer Centre
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 4A6
- Rekruttering
- Research St. Joseph's- Hamilton/St. Joseph's Healthcare Hamilton
-
Toronto, Ontario, Canada, M5G 1Z5
- Rekruttering
- University Health Network UHN - Princess Margaret Cancer Centre
-
-
Quebec
-
Montreal, Quebec, Canada, H2X 0A9
- Rekruttering
- Centre Hospitalier de L'Universite de Montreal
-
-
-
-
Central Jutland
-
Aarhus, Central Jutland, Danmark, 8200
- Rekruttering
- Aarhus University Hospital
-
-
-
-
Arizona
-
Tucson, Arizona, Forente stater, 85718
- Rekruttering
- Center for Neurosciences
-
-
Arkansas
-
Little Rock, Arkansas, Forente stater, 72211
- Rekruttering
- Arkansas Urology, North Little Rock
-
-
California
-
Los Angeles, California, Forente stater, 90017
- Rekruttering
- American Institute of Research
-
Los Angeles, California, Forente stater, 90080
- Rekruttering
- USC Kenneth Norris Jr Cancer Hospital
-
Orange, California, Forente stater, 92868
- Aktiv, ikke rekrutterende
- University of California, Irvine
-
San Diego, California, Forente stater, 92123
- Rekruttering
- Genesis Research, LLC - San Diego
-
-
Colorado
-
Denver, Colorado, Forente stater, 80210
- Rekruttering
- Advent Health
-
Lakewood, Colorado, Forente stater, 80228
- Rekruttering
- Colorado Urology - St. Anthony Hospital Campus
-
-
Connecticut
-
New Haven, Connecticut, Forente stater, 06519
- Rekruttering
- Yale School of Medicine
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forente stater, 20007
- Rekruttering
- Medstar Georgetown University Hospital
-
-
Florida
-
Sarasota, Florida, Forente stater, 34239
- Rekruttering
- Sarasota Memorial Healthcare System
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30322
- Rekruttering
- Emory University
-
Atlanta, Georgia, Forente stater, 30328
- Aktiv, ikke rekrutterende
- Georgia Urology
-
-
Idaho
-
Boise, Idaho, Forente stater, 83702
- Rekruttering
- Boise VA Medical Center
-
-
Illinois
-
Lisle, Illinois, Forente stater, 60532
- Rekruttering
- NextStage Clinical Research
-
-
Indiana
-
Indianapolis, Indiana, Forente stater, 46202
- Rekruttering
- Indiana University
-
-
Kansas
-
Wichita, Kansas, Forente stater, 67226
- Rekruttering
- Wichita Urology Group
-
-
Maryland
-
Annapolis, Maryland, Forente stater, 21401
- Rekruttering
- Anne Arundel Urology, PA
-
Hanover, Maryland, Forente stater, 21076
- Rekruttering
- Chesapeake Urology Research Associates
-
-
Mississippi
-
Southhaven, Mississippi, Forente stater, 38654
- Rekruttering
- The Urology Group P.C.
-
-
New Jersey
-
Morristown, New Jersey, Forente stater, 07960
- Rekruttering
- Atlantic Health
-
-
New York
-
Buffalo, New York, Forente stater, 14263
- Rekruttering
- Roswell Park Cancer Institute
-
Cheektowaga, New York, Forente stater, 14225
- Rekruttering
- Great Lakes Physician PC d/b/a Western new York Urology Associates
-
Lake Success, New York, Forente stater, 11042
- Rekruttering
- Northwell Health -The Arthur Smith Institute for Urology
-
New York, New York, Forente stater, 10010
- Rekruttering
- Veterans Affairs New York Harbor Healthcare System - Manhattan VA Medical Center
-
The Bronx, New York, Forente stater, 10468
- Rekruttering
- James J. Peters VA Medical Center
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45267
- Rekruttering
- University of Cincinnati
-
Columbus, Ohio, Forente stater, 43201
- Rekruttering
- OSU Arthur James Cancer Hospital
-
-
Pennsylvania
-
Bala-Cynwyd, Pennsylvania, Forente stater, 19004
- Rekruttering
- MidLantic Urology
-
Lancaster, Pennsylvania, Forente stater, 17601
- Rekruttering
- Keystone Urology Specialists
-
Philadelphia, Pennsylvania, Forente stater, 19104
- Rekruttering
- University of Pennsylvania - Perelman Center for Advanced Medicine - Penn Urology
-
Pittsburgh, Pennsylvania, Forente stater, 15232
- Rekruttering
- University of Pittsburgh Medical Center - Shadyside Medical Building
-
-
South Carolina
-
Myrtle Beach, South Carolina, Forente stater, 29572
- Rekruttering
- Carolina Urologic Research Center
-
-
Tennessee
-
Germantown, Tennessee, Forente stater, 38138
- Rekruttering
- The Conrad Pearson Clinic - Wolf River Office (Urology Center of the South)
-
Nashville, Tennessee, Forente stater, 37209
- Rekruttering
- Urology Associates, P.C.
-
-
Texas
-
Austin, Texas, Forente stater, 78759
- Rekruttering
- Urology Austin
-
Dallas, Texas, Forente stater, 75231
- Rekruttering
- Urology Clinics of North Texas PLLC (Dallas)
-
Dallas, Texas, Forente stater, 75390
- Rekruttering
- University of Texas Southwestern Medical Center - Urology Clinic
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- Houston Methodist Hospital (Houston)
-
-
Washington
-
Seattle, Washington, Forente stater, 98101
- Rekruttering
- Virginia Mason Medical Center
-
-
-
-
-
Paris, Frankrike, 75013
- Rekruttering
- Hopital La Pitie Salpetriere
-
-
Auvergne-Rhône-Alpes
-
Clermont-Ferrand, Auvergne-Rhône-Alpes, Frankrike, 63000
- Rekruttering
- CHU Clermont Ferrand - Hopital Gabriel Montpied
-
Lyon, Auvergne-Rhône-Alpes, Frankrike, 69003
- Rekruttering
- Hospices Civils de Lyon - Edouard Herriot Hosp.
-
-
Huate-Garonne
-
Toulouse, Huate-Garonne, Frankrike, 31059
- Rekruttering
- CHU Toulouse - Hopital Rangueil
-
-
Nantes
-
Nantes, Nantes, Frankrike, 44093
- Rekruttering
- CHU Nantes - Hotel Dieu
-
-
New Aquitaine
-
Bordeaux, New Aquitaine, Frankrike, 33076
- Rekruttering
- CHU de Bordeaux - Hôpital Pellegrin
-
-
Occitanie
-
Nîmes, Occitanie, Frankrike, 30900
- Rekruttering
- Centre Hospitalier Universitaire De Nimes (Nîmes)
-
-
Rhone.Alpe
-
Lyon, Rhone.Alpe, Frankrike, 69310
- Rekruttering
- Centre Hospitaliser Universitaire de Lyon Sud
-
-
Île-de-France Region
-
Paris, Île-de-France Region, Frankrike, 75018
- Rekruttering
- APHP - Hopital Bichat
-
-
-
-
Kuyavian-Pomeranian Voivodeship
-
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Polen, 85-048
- Rekruttering
- IN-VIVO Bydgoszcz
-
-
Wielkopolska
-
Poznan, Wielkopolska, Polen, 61731
- Rekruttering
- Clinical Research Center Spółka z ograniczoną odpowiedzialnością Medic-R Sp.k.
-
-
Woj. Mazowieckie
-
Warsaw, Woj. Mazowieckie, Polen, 02798
- Rekruttering
- Medical Concierge Centrum Medyczne
-
-
-
-
-
Madrid, Spania, 28033
- Rekruttering
- MD Anderson Cancer Center
-
Málaga, Spania, 29010
- Rekruttering
- Servicio Andaluz de Salud (SAS) - Hospital Universitario Virgen de la Victoria (HUVV)
-
-
Cantabria
-
Santander, Cantabria, Spania, 39008
- Rekruttering
- Instituto de Investigacion Valdecilla (IDIVAL) / Hospital universitario Marques de Valdecilla
-
-
Catalonia
-
Barcelona, Catalonia, Spania, 08036
- Rekruttering
- Hospital Clinic De Barcelona - University of Barcelona
-
Barcelona, Catalonia, Spania, 08003
- Rekruttering
- Hospital del Mar
-
-
Cordoba
-
Córdoba, Cordoba, Spania, 14004
- Rekruttering
- Hospital Universitario Reina Sofia
-
-
Galicia
-
A Coruña, Galicia, Spania, 15006
- Rekruttering
- Hospital Universitario de A Coruna
-
-
Madrid
-
Alcorcón, Madrid, Spania, 28922
- Rekruttering
- Hospital Universitario Fundacion Alcorcon
-
Madrid, Madrid, Spania, 28027
- Rekruttering
- Clinica Universidad de Navarra - Madrid
-
Madrid, Madrid, Spania, 28041
- Rekruttering
- Hospital Universitario 12 De Octubre (Madrid)
-
Madrid, Madrid, Spania, 28046
- Rekruttering
- Universidad Autonoma de Madrid. Hospital Universitario La Paz
-
-
Navarre
-
Pamplona, Navarre, Spania, 31008
- Rekruttering
- Clinica Universidad de Navarra - Pamplona
-
-
Vizcaya
-
Bilbao, Vizcaya, Spania
- Rekruttering
- Hospital Universitario Basurto
-
-
-
-
Gyeongsangnam-do
-
Yangsan, Gyeongsangnam-do, Sør -Korea, 50612
- Rekruttering
- Pusan National University Yangsan Hospital
-
-
Jeollanam-do
-
Hwasun, Jeollanam-do, Sør -Korea, 58128
- Rekruttering
- Chonnam National University Hwasun Hospital (CNUHH) Organisa
-
-
Seoul
-
Seoul, Seoul, Sør -Korea, 02841
- Rekruttering
- Korea University Anam Hospital
-
Seoul, Seoul, Sør -Korea, 06351
- Rekruttering
- Samsung Medical Center
-
Seoul, Seoul, Sør -Korea, 03722
- Rekruttering
- Severance Hospital, Yonsei University Health System
-
-
Songpa-gu
-
Seoul, Songpa-gu, Sør -Korea, 03080
- Rekruttering
- Seoul National University Hospital
-
-
-
-
Liberec Region
-
Liberec, Liberec Region, Tsjekkia, 46300
- Rekruttering
- Krajska Nemocnice Liberec
-
-
Prague
-
Prague, Prague, Tsjekkia, 15006
- Rekruttering
- Fakultni nemocnice v Motole
-
Prague, Prague, Tsjekkia, 16000
- Rekruttering
- Androgeos, spol. s r.o.
-
Prague, Prague, Tsjekkia, 14059
- Rekruttering
- Fakultní Thomayerova Nemocnice
-
-
Zlín
-
Kroměříž, Zlín, Tsjekkia, 76701
- Rekruttering
- Kromerizska Nemocnice A S
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Diagnosed, as documented, with carcinoma in situ (CIS) ±Ta/T1 high-grade disease.
- For T1 disease biopsies should contain muscle fibres.
-
Unresponsive to ≥2 courses of Bacillus Calmette-Guerin (BCG) therapy within the last 12 months. BCG-unresponsive refers to participants with high-grade non-muscle invasive bladder cancer (NMIBC) who are unlikely to benefit from and who will not be receiving further intravesical BCG. The term "BCG-Unresponsive" includes participants who did not respond to BCG treatment and have a persistent high-grade recurrence within 12 months after BCG was initiated, and those who despite an initial complete response to BCG, relapse with CIS within 12 months of their last intravesical treatment with BCG or relapse with high-grade Ta/T1 NMIBC within 6 months of their last intravesical treatment with BCG. The following criteria define the participants who may be included in the trial:
-
Have received at least 2 courses of BCG within a 12 month period - defined as at least 5 of 6 induction BCG instillations and at least 2 of 3 instillations of maintenance BCG, or at least 2 of 6 instillations of a second induction course, where maintenance BCG is not given.
o Exception: those who have T1 high-grade disease at 1st evaluation after induction BCG alone (at least 5 of 6 doses) may qualify in the absence of disease progression
-
At the time of tumour recurrence, participants with CIS alone or high-grade Ta/T1 with CIS should be within 12 months of last exposure to BCG
-
No maximum limit to the amount of BCG administered
-
All visible papillary tumours must be resected and those with persistent T1 disease on transurethral resection of bladder tumour (TURBT) should undergo an additional re-TURBT within 14 to 70 days prior to beginning trial treatment. Obvious areas of CIS should also be fulgurated
-
-
Eastern Cooperative Oncology Group (ECOG) status ≤2
-
Aged ≥18 years at the time of consent
-
Available for the whole duration of the trial
-
Life expectancy >2 years, in the opinion of the investigator
-
Absence of concomitant upper tract urothelial carcinoma or urothelial carcinoma within the prostatic urethra. Freedom from upper tract disease (if clinically indicated) as indicated by no evidence of upper tract tumour by either intravenous pyelogram, retrograde pyelogram, computed tomography (CT) scan with or without urogram, or magnetic resonance imaging (MRI) with or without urogram performed within 6 months of enrolment. Absence of locally advanced disease as assessed by CT scan or MRI
-
Participants who elect not to undergo cystectomy
-
Participants with prostate cancer on active surveillance at low risk for progression are permitted to be included into the trial at the discretion of the investigator
-
Females of reproductive potential must have a negative highly sensitive urine or serum pregnancy test upon entry into this trial and be willing to use highly effective contraception during treatment with the investigational medicinal product and for 6 months following the last dose. Otherwise, female participants must be post-menopausal (no menstrual period for a minimum of 12 months, as confirmed by follicle-stimulating hormone levels) or surgically sterile
-
Male subjects must be willing to use a male condom and effective contraception during sex throughout the treatment period and for 3 months following the last dose.
Exclusion Criteria:
-
Current or previous evidence of muscle-invasive (muscularis propria) or metastatic disease presented at the screening visit. Examples of increased risk of muscle-invasive disease include but are not limited to:
- Presence of lymphovascular invasion and / or micropapillary, sarcomatoid, plasmacytoid and / or neuroendocrine disease as shown in the histology of the biopsy sample
- Participants with CIS+T1 disease accompanied by the presence of hydronephrosis secondary to the primary tumour
-
Current systemic therapy for bladder cancer other than investigational medicinal products used in randomisation arm
-
Current or prior investigational treatment for BCG-unresponsive NMIBC or any other investigational drug (drug used in a clinical trial, i.e drug used in a Ferring sponsored non interventional study does not apply) within 1 month prior to screening
-
Current or prior pelvic external beam radiotherapy within 2 years of screening
-
Prior treatment with nadofaragene firadenovec at any time
-
Prior systemic therapy for bladder cancer at any time
-
Prior intravesical chemotherapy for the treatment of BCG-unresponsive NMIBC
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Nadofaragene firadenovec
Nadofaragene firadenovec (intravesical) |
vector-based gene therapy for NMIBC treatment to potentiate durable therapeutic responses by interferon (IFN) alfa-2b (IFN-α2b) amplification. It is a non-replicating recombinant adenovirus serotype 5 vector containing a transgene encoding the human IFN-α2b gene.
Andre navn:
|
|
Eksperimentell: Nadofaragene firadenovec + gemcitabine & docetaxel
Nadofaragene firadenovec (intravesical), and sequential gemcitabine and docetaxel (intravesical) |
vector-based gene therapy for NMIBC treatment to potentiate durable therapeutic responses by interferon (IFN) alfa-2b (IFN-α2b) amplification. It is a non-replicating recombinant adenovirus serotype 5 vector containing a transgene encoding the human IFN-α2b gene.
Andre navn:
Intravesical Gemcitabine chemotherapy, used in combination with Docetaxel. Intravesical Docetaxel chemotherapy, used in combination with Gemcitabine. |
|
Eksperimentell: Nadofaragene firadenovec + Pembrolizumab
Nadofaragene firadenovec (intravesical), and pembrolizumab (IV infusion). This arm will be closed and patients will no longer be randomised to this arm. This modification will convert ABLE-22 into a two-arm study with 1:1 randomisation between nadofaragene alone and nadofaragene + gemcitabine/docetaxel, to now N=100 in each of the 2 remaining arms. Participants already enrolled in this arm will not be impacted. |
vector-based gene therapy for NMIBC treatment to potentiate durable therapeutic responses by interferon (IFN) alfa-2b (IFN-α2b) amplification. It is a non-replicating recombinant adenovirus serotype 5 vector containing a transgene encoding the human IFN-α2b gene.
Andre navn:
Pembrolizumab is an FDA approved immune checkpoint inhibitor which restores the anti-tumour immune response by blocking the programmed cell death protein 1 (PD-1). Pembrolizumab is administered via intravenous (IV) infusion. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Complete response
Tidsramme: up to 6 months
|
Complete response (CR) at any time from first treatment (defined as absence of high-grade (HG) recurrence). |
up to 6 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Complete response at month 3
Tidsramme: 3 months
|
Complete response 3 months from first treatment |
3 months
|
|
Complete response at month 6
Tidsramme: 6 months
|
Complete response 6 months from first treatment |
6 months
|
|
Durability of complete response
Tidsramme: Up to 24 months
|
Durability of complete response (defined as time from achieved CR to HG recurrence, progression or death due to any cause). |
Up to 24 months
|
|
Muscle-invasive progression of disease
Tidsramme: up to 36 months
|
Muscle-invasive progression of disease (defined as time from first treatment to first evidence of muscle-invasive disease or death) |
up to 36 months
|
|
Cystectomy-free survival
Tidsramme: up to 36 months
|
Cystectomy-free survival (defined as time from first treatment to either cystectomy or death due to any cause) |
up to 36 months
|
|
Pathological staging
Tidsramme: up to 36 months
|
Pathological staging (tumor, node, metastasis staging system) in participants at time of cystectomy |
up to 36 months
|
|
Overall survival
Tidsramme: up to 36 months
|
Overall survival (defined as time from first treatment to death due to any cause) |
up to 36 months
|
|
Evidence of malignant lesions of the upper tract and/or prostatic urethra
Tidsramme: up to 24 months
|
Evidence of malignant lesions of the upper tract and/or prostatic urethra (defined as time from first treatment to first evidence of malignant lesions). |
up to 24 months
|
|
Adverse events
Tidsramme: up to 36 months
|
Adverse events collected for nadofaragene firadenovec in combination with chemotherapy (gemcitabine and docetaxel) or immunotherapy (pembrolizumab) |
up to 36 months
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Global Clinical Compliance, Ferring Pharmaceuticals
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 000434
- U1111-1299-0176 (Annen identifikator: World Health Organization)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .